Fighting a cunning cancer opponent

July 18, 2013

(Medical Xpress)—It was a classic eureka moment. In 2006 Mary Bebawy was listening to a lecture outside her area of research when suddenly the intellectual penny dropped. "My mind went elsewhere. I didn't hear the rest of the lecture," says the University of Technology, Sydney (UTS) cancer researcher and pharmaceutical scientist.

"Elsewhere'' in this case was to a possible explanation of how cancer cells rapidly become resistant to the arsenal of anti-cancer drugs tossed at them. It was as if they shared secrets with one another, she imagined.

Seven years on that unexpected insight has proven correct. After teaming up with the scientist who sparked her eureka moment – Sydney University vascular Georges Grau – Associate Professor Bebawy has found that drug-resistant cancer cells really do communicate with other cells, healthy or otherwise. And they do so in a surprising way.

"We discovered that a resistant cancer cell can shed tiny , or micro particles, from its surface,'' Professor Bebawy explains, adding that inside these micro particles is genetic material and large molecules called proteins which confer . In a nutshell, the proteins pump drugs out of a treated cell.

"The dock onto a drug-sensitive cancer cell and within two hours they release their contents into the cell. As early as four hours later that cell is multi-drug resistant cancer cell," Professor Bebawy says.

But it gets worse. In April, Professor Bebawy presented new findings to a specialist science conference in Boston. Not only can transfer resistance to drug-sensitive cells, they can also mop up and sequester from the , rendering them useless. "The patients have roughly 50 per cent less drug in their body," she says.

The implications are clear. Cancer cells are survivors. "I'm in awe of the inherent capacity of cells to survive. It's an evolutionarily conserved pathway. It's quite remarkable," says Professor Bebawy who now has National Health & Medical Research Council funding.

While cancer cells are cunning opponents, if Professor Bebawy and her team of 10 UTS doctoral students can tease out all their tricks it should be possible to design drugs able to circumvent them or tests that can detect developing drug resistance. The latter would help clinicians keep up with the adaptive cancer cells.

Working with collaborators such as Professor Grau and cancer specialists at Royal Prince Alfred and Concord hospitals, the UTS team is developing a blood test for identifying the resistance proteins in patients with Myeloma, a bone marrow disease. Currently, the only way to do this is with highly invasive biopsies from the bone marrow.

It's early stages for clinical applications of the micro particle work but Professor Bebawy – who has seen cancer in her own family – is confident they're gaining the upper hand, based on a growing body of scientific evidence detailing the devious survival skills of cells.

So, today it's obvious can communicate drug resistance to other cells. But as with any new field of research that wasn't the case in 2006. Just finding funding to explore this blue-sky hypothesis was tough.

Eventually, the NSW Cancer Council took a chance. "In 2009 they gave me $120,000 per year for three years,'' Professor Bebawy says. "It allowed me to employ a research assistant and do the experiments. The fact they believed in me, I'm forever grateful."

That initial support enabled professors Bebawy and Grau and their colleagues to publish their first paper on the micro particle mechanism in the journal Leukemia in 2009. That too was challenging.

"It's a new area so initially it was very difficult to get the work published. It was really out there," Professor Bebawy says. "Finally, the work is acknowledged. It's a huge team effort."

A team effort that was based on one eureka moment in the mind of one scientist. "That's why I encourage students to read outside their area to attend unrelated seminars," she says. "You may get an idea".

Explore further: Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors

Related Stories

Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors

June 15, 2013
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute ...

Breast cancer researchers find new drug target companion prognostic test for hormone therapy resistance

April 1, 2013
A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive ...

Team finds gene that promotes drug resistance in cancer

January 14, 2013
Scientists from the University of Iowa and Brigham Young University (BYU) have identified a gene that may be a target for overcoming drug resistance in cancer. The finding could not only improve prognostic and diagnostic ...

Genetic screen finds new treatment targets for lung cancer

July 9, 2013
Cancer Research UK scientists are the first to use an efficient new screening strategy to identify gene faults in tumour cells that are possible drug targets for the most common form of lung cancer, according to new research ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.